24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
LENALIEVA 10MG is an Capsules medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | LENALIEVA 10MG |
|---|---|
| Composition | Lenalidomide Capsules 10mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Capsules |
| Packaging | Btl (30 cap) |
| Country of Origin | India |
LENALIEVA 10MG (Lenalidomide Capsules 10mg) is a widely used Capsules medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
LENALIEVA 10 MG (Lenalidomide Capsules 10 mg) is a prescription anticancer and immunomodulatory medicine containing Lenalidomide 10 mg, a widely used treatment for specific blood cancers and bone marrow disorders. It belongs to the class of medicines known as Immunomodulatory Agents (IMiDs), which work by enhancing the body's immune response against cancer cells, inhibiting abnormal cell growth, and reducing the formation of blood vessels that support tumor development.
Lenalidomide has become a key component of modern hematology and oncology treatment protocols due to its ability to target cancer through multiple mechanisms. It helps strengthen immune system activity, suppresses cancer cell proliferation, and interferes with the microenvironment that allows cancer cells to survive and spread.
LENALIEVA 10 MG is commonly prescribed for the treatment of Multiple Myeloma, Myelodysplastic Syndromes (MDS) associated with deletion 5q abnormalities, Mantle Cell Lymphoma (MCL), and certain other hematological malignancies. It may be used as part of combination therapy or maintenance treatment depending on the patient's condition and clinical requirements.
The 10 mg strength is frequently used for individualized treatment plans, dose adjustments, maintenance therapy, and patients requiring lower doses based on treatment response or kidney function.
LENALIEVA 10 MG is commonly prescribed for:
Manufactured according to stringent pharmaceutical quality standards, LENALIEVA 10 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Lenalidomide therapy require regular blood count monitoring, kidney function testing, liver assessments, and routine clinical evaluations to ensure optimal treatment outcomes and safety.
Due to its proven efficacy and versatile clinical applications, LENALIEVA 10 MG remains an important medicine in modern hematology and oncology care.
LENALIEVA 10 MG (Lenalidomide Capsules 10 mg) is primarily used for the treatment and management of certain blood cancers and bone marrow disorders.
The medicine is widely prescribed for newly diagnosed, relapsed, and refractory multiple myeloma patients.
Lenalidomide may be used as maintenance treatment following successful multiple myeloma therapy.
The medicine helps manage selected forms of MDS, especially those associated with deletion 5q abnormalities.
Doctors may prescribe Lenalidomide for patients with relapsed or refractory mantle cell lymphoma.
The medicine may be incorporated into treatment protocols for various blood-related cancers.
Lenalidomide supports prolonged remission and disease management in eligible patients.
The medicine is often used with corticosteroids and other anticancer therapies.
Lenalidomide belongs to a class of medicines known as Immunomodulatory Agents (IMiDs).
LENALIEVA works by:
This multi-targeted mechanism contributes to improved outcomes in patients with blood cancers and related disorders.
Like all medicines, LENALIEVA 10 MG may cause side effects in some patients. The severity and frequency of side effects vary among individuals.
Weakness and tiredness are commonly reported during treatment.
The medicine may decrease white blood cells, red blood cells, and platelet counts.
Digestive disturbances such as constipation may occur.
Some patients may experience diarrhea.
Mild to moderate nausea may develop.
Muscle pain or cramping may occur during therapy.
Skin reactions may develop in some individuals.
Patients may occasionally experience dizziness.
Loss of appetite may affect nutritional intake.
Seek immediate medical attention if you experience:
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of LENALIEVA 10 MG (Lenalidomide Capsules 10 mg) should always be determined by a qualified healthcare professional.
Treatment recommendations vary according to the disease being treated.
Patients with kidney impairment may require dosage adjustments.
Regular laboratory monitoring helps guide treatment decisions.
Doctors may modify dosage according to effectiveness and tolerability.
Concurrent medications may influence treatment schedules and dosing.
Before starting treatment, inform your doctor if you have:
Lenalidomide can cause severe birth defects and should never be used during pregnancy. Effective contraception and strict pregnancy prevention measures are required during treatment.
Patients should also disclose all prescription medicines, supplements, vitamins, and herbal products they are taking to avoid potential drug interactions.
It is used for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, and certain blood-related cancers.
Lenalidomide is an immunomodulatory medicine that helps the immune system fight cancer cells and slows tumor growth.
It is generally classified as an immunomodulatory anticancer medicine rather than traditional chemotherapy.
Yes. It is frequently prescribed as maintenance treatment for multiple myeloma patients.
Yes. It may reduce white blood cells, red blood cells, and platelet counts, requiring regular monitoring.
The 10 mg strength is often used for maintenance therapy, individualized dosing, or patients requiring dose adjustments.
Yes. Lenalidomide can cause severe birth defects, making strict pregnancy prevention measures essential.
Yes. This medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and hematology treatment.